Activity of acetylcholinesterase in CSF increases in Alzheimer's patients after treatment with tacrine

Alzheimer's Reports

Volumn 2, Issue 6, 1999, Pages 347-352

  Nordberg, Agneta ^a,b   Hellström Lindahl, Ewa ^a,b   Almkvist, Ove ^a,b   Meurling, Lennart ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cerebrospinal fluid; Tacrine 1 hydroxy tacrine

Indexed keywords

EID: 22844455678     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Alhainen K, Partanen J, Reinikainen K et al. (1991).. Discrimination of tetrahydroaminocridine responders by a single phamnacoEEG in patients with Alzheimer's disease. Neurosci Lett 127, 113-116.
2. Alvarez A, Alarcôn R and Opazo C (1998). Stable compexes involving acetylcholinesterase and amyloid-p peptide changes in biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 18,3213-3223.
3. Arendt T, Bruckner MK, Lange M and Bigl V (1992). Changes in acetylchoiinesterase and butylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 21,381-396.
4. Cutler NR, Poninsky RJ, Sramek JS et al. (1998). Dose dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta A/euro/ Scand 97,244-250.
5. Davies P (1979). Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171,319-327.
6. Ekman L, Lindström B and Roxin P (1989). Determination of tacrine and the 1-hydroxy metabolite in plasma using HLPC. J Chromatog494,397-402.
7. Ellman GL, Coumey KD, Andres V and Featherstone RM (1961 ). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7,88-95.
8. Folstein MF, Folstein SE and McHugh PR (1975). "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12,189-198.
9. Ford JM, Truman CA, Wilcock GK and Roberts CJC (1993). Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 53, 691695.
10. Friedman A, Kauter D, Shermer J et al. (1996). Pyridostigmine brain penetration under stress enhance neuronal excitability and induces early immetidate transcriptional response. Nature Med2,1382-1385.
11. Giacobini E (1997). From molecular structure to Alzheimer therapy. Jpn J Pharmacol 74,225-241.
12. Iyo M, Namba H, Fukushi K, Shinotoh H et al. (1997). Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349,1805-1809.
13. Jelic V, DierksT, Amberla K, Almkvist O et al. (1998). Longitudinal changes in quantitative EEC during long-term tacrine treatment of patients with Alzheimer's disease. Neurosci Lett 254,85-88.
14. Johansson M, Hellström-Lindahl E and Nordberg A (1996). Steadystate pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. Dementia 7,111-117.
15. Kaufer D, Friedman A, Scidman S and Soreq H (1998). Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393,373-377.
16. Knopman DS, Schneider L, Davis K, Talwalker S et al. (1996). Longterm tacrine (Cognex). treatment: effect of nursing home placement and mortality. Neurology 47,166-177.
17. Kühl DE, Koeppe RA, Minoshima S étal. (1999). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52,691-699.
18. Lucotte G, Oddoze C and Michel BF (1996). Apolipoprotein E genotype allele e4 and response to tacrine in Alzheimer's disease. Alz Res 2,101-102.
19. Macgowan SH, Wilcock GK and Scott M (1998). Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriat Psychiatr 13, 625-630.
20. Masters CL and Beyreuther K (1998). Alzheimer's disease. BrMed J 316,446-448.
21. Mesulam MM, Geula C and Morén A (1987). Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol 22,683-691.
22. McKhann G, Drachman D, Folstein M, Katzman R ef aJ. (1984). Clinical diagnosis of Alzheimer's disease. Report of the NI NCDSADRDA work group under the auspices of the Department of Health and Human Services. Task force on Alzheimer's disease. Neurology34,939-944.
23. Minthon L, Gustafson L, Dalfelt G ef at. (1993). Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow. Dementia 4, 32-42.
24. Minthon L, Nilsson K, Edvinsson L et aJ.(1995). Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. Dementia 6,245-251.
25. Poirier J, Delisle M-C, Quirion R étal. (1995). Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc NatlAcad Sci USA 92,1226012264.
26. Nordberg A, Amberia K, Shigeta M et al. (1998). Long-term tacrine treatment in three mild Alzheimer patients: Effect on nicotinic receptors, cerebral blood flow, glucose metabolism, EEC, and cognitive abilities. Alz Dis Assoc Disord 12,228-237.
27. Nordberg A, Hartvig P, Lilja A et aJ.(1992). Tacrine restores cholinergic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. NeurobiolAging 13,747-758.
28. Nordberg A, Lundqvist H, Hartvig P et al. (1997). Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dementia GeriatrCogn Disord 8,78-84.
29. Nordberg A and Svensson AL (1998). Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology. Drug Safety 19,465-480.
30. Oddoze C, Michel BF, Berthézéne P et al. (1998). Apolipoprotein E e4 allele predicts a positive response to tacrine in Alzheimer's disease. Alz Reports 1,13-16.
31. Perry EK, Perry RH, Blessed G and Tomlinson BE (1978). Changes in brain cholinesterases in senile dementia of the Alzheimer type. NeuropatholApplNeurobiolA, 273-277.
32. Sherman KA (1991 ). Pharmacodynamics of oral E2020 and tacrine in humans: Novel approaches. In: Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. Birkhäuser, Boston: pp 321-328.
33. Shigeta M, Persson A, Viitanen M et at. (1993). EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA). in Alzheimer's disease. Acta Neurol Scand suppl 149,62-65.
34. Svensson AL and Nordberg A (1998). Tacrine and donepezil attenuate the neurotoxic effect of Aβ (25-35). in rat PC12 cells. NeuroReportQ, 1519-1522.
35. Svensson AL, Zhang X and Nordberg A (1996). Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. Brain Res 726,207-212.
36. Ulrich J, Meier-Rüge W and Probst A (1990). Senile plaques: staining for acetylcholinestesterase and A4 protein. A comparative study in the hippocampus and entorhinal cortex. Acta NeuropatholBO, 624-628.
37. von der Kammer H, Mayhaus M, Albrecht C er al. (1998). Muscarinic acetylcholine receptors activate expression of the Egr gene family of transcription factors. J Biol Chem 273,1453814544.